Resverlogix Corp.

Events/Webcasts

Webcasts

June 17, 2015: Resverlogix presented at the BIO International Convention 2015. Click here to access the archived webcast: http://www.veracast.com/webcasts/bio/internationalconvention2015/22203242375.cfm

Resverlogix in the Media

Aug. 26, 2015: Resverlogix featured in the Life Sciences Report: Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey. Access article here: /upload/media_element/218/01/donald-mccaffrey-lsr-interview-8-26-15.pdf

June 25, 2015: Resverlogix’s Dr. Ewelina Kulikowski has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.” Access article here: http://www.resverlogix.com/upload/media_element/213/01/ebr_july-15_pp.76-79-resverlogix-corp.pdf 

April 22, 2015: Donald McCaffrey, President & CEO on BNN’s Business Day
 

April 27, 2015- BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China. Link here: http://www.biocentury.com/dailynews/company/2015-04-27/hepalink-gains-rights-to-resverlogixs-rvx-208-in-china

April 28, 2015- BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne. Link here to access the full article.

April 28, 2015- Bloomberg Business: Resverlogix in Discussions to Be Bought, by Eric Lam. Link here: http://www.bloomberg.com/news/articles/2015-04-28/resverlogix-ceo-says-company-in-discussions-to-be-bought

April 28, 2015- BioSpace Breaking News: Resverlogix (RVX.TO) CEO Says It’s in Talks With Suitors, After $100M in Q1 Deals, by Riley McDermid. Link here: http://www.biospace.com/News/with-almost-a-100-million-in-deals-for-q1/374186?source=sm&type=twitter_resverlogix042815

April 28, 2015- Fierce Biotech: Resverlogix gets a $116M China Drug development deal, stokes buyout buzz, by John Carroll. Link here: http://www.fiercebiotech.com/story/resverlogix-gets-116m-china-drug-development-deal-stokes-buyout-buzz/2015-04-28

April 28, 2015 - GEN News Highlights: Hepalink Buys China-Area Rights to Resverlogix's CV Candidate for Up-to-$441.5M Link here: http://www.genengnews.com/gen-news-highlights/hepalink-buys-china-area-rights-to-resverlogix-s-cv-candidate-for-up-to-441-5m/81251205/

Events - July to September 2015

Resverlogix will be attending several key industry conferences. Not all events offer a presentation opportunity. Please note this list is not exhaustive and subject to change.

Alzheimer's Association Research Roundtable (AAIC) 2015, Washington, DC, July 18-23.

EpiCongress Boston 2015, Boston, MA, July 22-24.

European Society of Cardiology (ESC) Congress 2015, London, England, August 29 - Sept. 2. 

17th Annual Global Investment Conference Rodman & Renshaw 2015, New York City, NY, Sept. 8-10. 

51st Annual European Association for the Study of Diabetes (EASD), Stockholm, Sweden, Sept.14-18.

GCFF Investment Conference,Toronto, ON, Sept. 26. 

Resverlogix Annual General Meeting (AGM), Calgary, AB, Sept. 30.  

To arrange a meeting with senior management, please contact Sarah Zapotichny, Director of Investor Relations & Corporate Communications at sarah@resverlogix.com